SIGLEC7 and neoplasm: Antibodies against SIGLEC-7 and SIGLEC-9 can suppress the conversion of macrophages into tumor-associated macrophages and reprogram the immunosuppressive tumor microenvironment, enhancing anti-cancer immunity [213].